548 related articles for article (PubMed ID: 33951415)
1. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
[TBL] [Abstract][Full Text] [Related]
2. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.
Räber L; Ueki Y; Otsuka T; Losdat S; Häner JD; Lonborg J; Fahrni G; Iglesias JF; van Geuns RJ; Ondracek AS; Radu Juul Jensen MD; Zanchin C; Stortecky S; Spirk D; Siontis GCM; Saleh L; Matter CM; Daemen J; Mach F; Heg D; Windecker S; Engstrøm T; Lang IM; Koskinas KC;
JAMA; 2022 May; 327(18):1771-1781. PubMed ID: 35368058
[TBL] [Abstract][Full Text] [Related]
3. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.
Rexhaj E; Bär S; Soria R; Ueki Y; Häner JD; Otsuka T; Kavaliauskaite R; Siontis GC; Stortecky S; Shibutani H; Spirk D; Engstrøm T; Lang I; Morf L; Ambühl M; Windecker S; Losdat S; Koskinas KC; Räber L;
Atherosclerosis; 2024 May; 392():117504. PubMed ID: 38513436
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy.
Biccirè FG; Häner J; Losdat S; Ueki Y; Shibutani H; Otsuka T; Kakizaki R; Hofbauer TM; van Geuns RJ; Stortecky S; Siontis GCM; Bär S; Lønborg J; Heg D; Kaiser C; Spirk D; Daemen J; Iglesias JF; Windecker S; Engstrøm T; Lang I; Koskinas KC; Räber L
J Am Coll Cardiol; 2023 Oct; 82(18):1737-1747. PubMed ID: 37640248
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.
Otake H; Sugizaki Y; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Kawamori H; Shinke T; Hirata KI
J Cardiol; 2019 Mar; 73(3):228-232. PubMed ID: 30579806
[TBL] [Abstract][Full Text] [Related]
6. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.
Ako J; Hibi K; Kozuma K; Miyauchi K; Morino Y; Shinke T; Tsujita K; Uno K; Kawabata Y; Hiro T
J Cardiol; 2018 Jun; 71(6):583-589. PubMed ID: 29606415
[TBL] [Abstract][Full Text] [Related]
7. Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study.
Räber L; Koskinas KC; Yamaji K; Taniwaki M; Roffi M; Holmvang L; Garcia Garcia HM; Zanchin T; Maldonado R; Moschovitis A; Pedrazzini G; Zaugg S; Dijkstra J; Matter CM; Serruys PW; Lüscher TF; Kelbaek H; Karagiannis A; Radu MD; Windecker S
JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 1):1518-1528. PubMed ID: 30553686
[TBL] [Abstract][Full Text] [Related]
8. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.
Gao F; Wang ZJ; Ma XT; Shen H; Yang LX; Zhou YJ
Lipids Health Dis; 2021 Sep; 20(1):106. PubMed ID: 34511134
[TBL] [Abstract][Full Text] [Related]
9. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
10. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.
Räber L; Taniwaki M; Zaugg S; Kelbæk H; Roffi M; Holmvang L; Noble S; Pedrazzini G; Moschovitis A; Lüscher TF; Matter CM; Serruys PW; Jüni P; Garcia-Garcia HM; Windecker S;
Eur Heart J; 2015 Feb; 36(8):490-500. PubMed ID: 25182248
[TBL] [Abstract][Full Text] [Related]
11. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ
JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172
[TBL] [Abstract][Full Text] [Related]
12. Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial.
Bär S; Kavaliauskaite R; Otsuka T; Ueki Y; Häner JD; Siontis GCM; Stortecky S; Shibutani H; Temperli F; Kaiser C; Iglesias JF; Jan van Geuns R; Daemen J; Spirk D; Engstrøm T; Lang I; Windecker S; Koskinas KC; Losdat S; Räber L
EuroIntervention; 2023 Jul; 19(4):e286-e296. PubMed ID: 37341586
[TBL] [Abstract][Full Text] [Related]
13. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
[TBL] [Abstract][Full Text] [Related]
14. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Schwartz GG; Bessac L; Berdan LG; Bhatt DL; Bittner V; Diaz R; Goodman SG; Hanotin C; Harrington RA; Jukema JW; Mahaffey KW; Moryusef A; Pordy R; Roe MT; Rorick T; Sasiela WJ; Shirodaria C; Szarek M; Tamby JF; Tricoci P; White H; Zeiher A; Steg PG
Am Heart J; 2014 Nov; 168(5):682-9. PubMed ID: 25440796
[TBL] [Abstract][Full Text] [Related]
15. Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial.
Ako J; Hibi K; Tsujita K; Hiro T; Morino Y; Kozuma K; Shinke T; Otake H; Uno K; Louie MJ; Takagi Y; Miyauchi K
Circ J; 2019 Sep; 83(10):2025-2033. PubMed ID: 31434809
[TBL] [Abstract][Full Text] [Related]
16. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
Yano H; Horinaka S; Ishimitsu T
J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548
[TBL] [Abstract][Full Text] [Related]
17. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial.
Ueki Y; Häner JD; Losdat S; Gargiulo G; Shibutani H; Bär S; Otsuka T; Kavaliauskaite R; Mitter VR; Temperli F; Spirk D; Stortecky S; Siontis GCM; Valgimigli M; Windecker S; Gutmann C; Koskinas KC; Mayr M; Räber L
Thromb Haemost; 2024 Jun; 124(6):517-527. PubMed ID: 37595625
[TBL] [Abstract][Full Text] [Related]
18. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C;
Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832
[TBL] [Abstract][Full Text] [Related]
19. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
Liang D; Li C; Tu Y; Li Z; Zhang M
Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
[TBL] [Abstract][Full Text] [Related]
20. Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging.
Abrahams T; Fujino M; Nelson AJ; Nicholls SJ
Curr Opin Cardiol; 2023 Nov; 38(6):504-508. PubMed ID: 37751373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
